Data di Pubblicazione:
2019
Citazione:
P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database / M.P. Abbracchio, J.-. Boeynaems, J.L. Boyer, G. Burnstock, S. Ceruti, M. Fumagalli, C. Gachet, R. Hills, R.G. Humphries, K. Inoue, K.A. Jacobson, C. Kennedy, B.F. King, D. Lecca, C.E. Müller, M.T. Miras-Portugal, V. Ralevic, G.A. Weisman. - In: IUPHAR/BPS GUIDE TO PHARMACOLOGY CITE. - ISSN 2633-1020. - 2019:4(2019), pp. 1-26. [10.2218/gtopdb/F52/2019.4]
Abstract:
P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor' or 'P2Y1 -like', etc., until further, as yet undefined, corroborative criteria can be applied [46,109, 187, 375, 388]. Clinically used drugs acting on these receptors include the dinucleoside polyphosphatediquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease 2[ 36], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [52, 316].
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
M.P. Abbracchio, J.-. Boeynaems, J.L. Boyer, G. Burnstock, S. Ceruti, M. Fumagalli, C. Gachet, R. Hills, R.G. Humphries, K. Inoue, K.A. Jacobson, C. Kennedy, B.F. King, D. Lecca, C.E. Müller, M.T. Miras-Portugal, V. Ralevic, G.A. Weisman
Link alla scheda completa: